Abstracts tagged "dermatomyositis"

Abstract Number: 044 • 2020 Pediatric Rheumatology Symposium
Nailing Down Nailfold Capillaroscopy Practices: A Survey of Pediatric Rheumatologists Within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Network
Sonia Savani¹, Natasha Ruth ², Paul Nietert ¹, Gabrielle Morgan ³, Mileka Gilbert ¹ and Lauren Pachman ⁴, ¹Medical University of South Carolina, Charleston, South Carolina, ²Medical University South Carolina, Charleston, South Carolina, ³Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, Illinois, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, 303 E Superior, Chicago
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare systemic autoimmune disease characterized by vasculopathy and rash. The Bohan-Peter criteria for dermatomyositis are not ideal. There is…
Abstract Number: 1290 • 2019 ACR/ARP Annual Meeting
Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy
Iago Pinal-Fernandez¹, Maria Casal-Dominguez ¹, Assia Derfoul ¹, Katherine Pak ¹, Paul Plotz ¹, Frederick W. Miller ², Jose C Milisenda ³, Josep M Grau-Junyent ³, Albert Selva-O'Callaghan ⁴, Julie Paik ⁵, Jemima Albayda ⁶, Lisa Christopher-Stine ⁷, Thomas E Lloyd ⁵, Andrea M Corse ⁵ and Andrew L Mammen ¹, ¹National Institutes of Health, Bethesda, ²NIEHS, NIH, Bethesda, MD, ³Clinic Hospital, Barcelona, ⁴Department of Systemic Autoimmune Diseases, Hospital Universitario Valle de Hebron, Barcelona, Spain, Barcelona, ⁵Johns Hopkins, Baltimore, ⁶Johns Hopkins University, Baltimore, MD, ⁷Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Activation of the type 1 interferon (IFN1) pathway is a prominent feature of dermatomyositis (DM) muscle and may play a role in the pathogenesis…
Abstract Number: 1296 • 2019 ACR/ARP Annual Meeting
Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema
Majid Zeidi¹, Kristen Chen ¹, Basil Patel ², Rachel Lim ³ and Victoria Werth ¹, ¹Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ³Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA, Philadelphia
Background/Purpose: Dermatomyositis (DM) is conventionally characterized by interface dermatitis (ID) on skin histopathology. A subset of patients with clinically diagnosed DM have skin biopsies showing…
Abstract Number: 1866 • 2019 ACR/ARP Annual Meeting
Gene Expression Meta-Analysis Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues
Jessica Neely¹, Dmitry Rychkov ¹, Manish Paranjpe ¹, Michael Waterfield ², Susan Kim ¹ and Marina Sirota ², ¹University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco
Background/Purpose: Dermatomyositis (DM) is a complex immune-mediated disease resulting in muscle and skin inflammation. Prior studies of gene expression in DM have revealed a type…
Abstract Number: 1869 • 2019 ACR/ARP Annual Meeting
Myeloid Dendritic Cells (mDCs) Are Major Producers of Interferon-β in Dermatomyositis and Higher Numbers of mDCs Are Found in Hydroxychloroquine Nonresponders
Kristen Chen¹, Majid Zeidi ¹, Maria Wysocka ², Nithin Reddy ¹, Arvin Jadoo ¹, Muhammad Bashir ¹, Sarah Ahmed ², Basil Patel ², Kevin Zhang ², Barbara White ³ and Victoria Werth ¹, ¹Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ³Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Dermatomyositis (DM) is an autoimmune disease affecting the skin, skeletal muscle, lungs, and/or other organs. While the pathogenesis remains poorly understood, it is thought…
Abstract Number: 1933 • 2019 ACR/ARP Annual Meeting
Tumorigenesis Related Gene Identification in Dermatomyositis Using Meta-Analysis
Jihad Aljabban¹, Saad Syed ², Sharjeel Syed ³, Kalyn Hoffman ⁴, Laith Hasan ⁵, Nikhil Adapa ¹, Zahir Allarakhia ⁶, Dexter Hadley ⁷, Mohamad Aljabban ⁸ and Wael Jarjour ⁹, ¹Ohio State University College of Medicine, Columbus, ²Stanford School of Medicine, Stanford, ³Stanford School of Medicine, Stanford, CA, ⁴The Ohio State University College of Medicine, Columbus, OH, ⁵Tulane School of Medicine, New Orleans, ⁶Ohio State University College of Medicine, Columbus, OH, ⁷Institute for Computational Health Sciences, San Francisco, ⁸Genesys Health Systems, Grand Blanc, MI, ⁹Ohio State College of Medicine, Columbus, OH
Background/Purpose: Dermatomyositis (DM) is a progressive, systemic autoimmune disease-causing inflammatory changes in the skin and skeletal muscles. DM is associated with carcinomas of the ovary,…
Abstract Number: 1934 • 2019 ACR/ARP Annual Meeting
Tripartite Motif (TRIM) Gene Family Expression in Dermatomyositis
Jihad Aljabban¹, Sharjeel Syed ², Saad Syed ³, Zarife Sahenk ⁴, Noah Weisleder ⁵, Kevin McElhanon ⁵, Kalyn Hoffman ⁶, Nikhil Adapa ¹, Zahir Allarakhia ⁷, Laith Hasan ⁸, Dexter Hadley ⁹, Mohamad Aljabban ¹⁰ and Wael Jarjour ¹¹, ¹Ohio State University College of Medicine, Columbus, ²Stanford School of Medicine, Stanford, CA, ³Stanford School of Medicine, Stanford, ⁴Department of Neurology, Research Institute at Nationwide Children’s Hospital, Columbus, OH, ⁵Dorothy M. Davis Heart and Lung Research Institute & Dept. of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶The Ohio State University College of Medicine, Columbus, OH, ⁷Ohio State University College of Medicine, Columbus, OH, ⁸Tulane School of Medicine, New Orleans, ⁹Institute for Computational Health Sciences, San Francisco, ¹⁰Genesys Health Systems, Grand Blanc, MI, ¹¹Ohio State College of Medicine, Columbus, OH
Background/Purpose: Dermatomyositis (DM) is a progressive, systemic autoimmune disease causing inflammatory changes to the skin and skeletal muscles. TRIM family proteins are composed of approximately…
Abstract Number: 93 • 2019 ACR/ARP Annual Meeting
Interferon Pathway Activation in T Follicular Helper (Tfh) Cell Subsets in Human Myositis
Amrutesh Puranik¹, Mark Jensen ², Regine Tipon ³, Yogita Ghodke-Puranik ³, Valeria Mezzano ⁴, Shanmugapriya Selvaraj ⁵, Theresa Wampler Muskardin ⁴, Cynthia Loomis ⁴, Ann Reed ⁶, Lauren Pachman ⁷ and Timothy Niewold ⁵, ¹NYU Langone Health, New York, NY, ²Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ³Colton Center for Autoimmunity, NYU School of Medicine, New York, ⁴New York University Langone Health, New York, ⁵New York University Langone Health, New York, NY, ⁶Duke University School of Medicine, Durham, NC, ⁷Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Background/Purpose: T and B cells come together in ectopic lymphoid aggregates in myositis, suggesting that local T:B cell interactions could play a role in disease. …
Abstract Number: 2739 • 2019 ACR/ARP Annual Meeting
Skin Disease Activity and Autoantibody Phenotype Are Major Determinants of Blood Interferon Signatures in Dermatomyositis
Mika Tabata¹, Kavita Sarin ², Karen Page ³, Christine Huard ³, Shanrong Zhao ³, Donald Bennett ³, Jillian Johnson ³, Kristen Johnson ³ and David Fiorentino ², ¹Stanford University School of Medicine, Stanford, CA, ²Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ³Pfizer, Boston
Background/Purpose: Interferon (IFN) signaling is upregulated in dermatomyositis (DM) and thought to play a role in pathogenesis. An IFN gene signature in peripheral blood of…
Abstract Number: 395 • 2019 ACR/ARP Annual Meeting
Younger Age at Presentation Is a Risk Factor for Failure to Achieve Remission in Adult Dermatomyositis
Soumyasri Kambhatla¹, Carrie Richardson ², Prasanth Lingamaneni ³ and Augustine Manadan ², ¹John H. Stroger Hospital of Cook County, Chicago, ²Rush University Medical Center, Chicago, IL, ³John H. Stroger Hospital of Cook County, Chicago, IL
Background/Purpose: A subset of patients with dermatomyositis may fail to achieve remission despite treatment. Nevertheless, the risk factors for failure to achieve remission in dermatomyositis are largely…
Abstract Number: 2841 • 2019 ACR/ARP Annual Meeting
A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis
Yoo Jung Kim¹, Elena Schiopu ², Katalin Dankó ³, Tahseen Mozaffar ⁴, Srinivas Chunduru ⁵, Kirstin Lees ⁶, Namita Goyal ⁴, David Fiorentino ⁷ and Kavita Sarin ⁷, ¹Stanford University School of Medicine, Redwood City, CA, ²Department of Rheumatology, University of Michigan, Ann Arbor, ³Department of Clinical Immunology, Medical Faculty, University of Debrecen, Debrecen, Hungary, ⁴Department of Neurology, University of California Irvine, Irvine, CA, ⁵Idera Pharmaceuticals, Inc., Cambridge, MA, ⁶Idera Pharmaceuticals, Inc., Cambridge, ⁷Department of Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a rare inflammatory disease of skin and muscle associated with characteristic skin findings, muscle weakness, interstitial lung disease, pruritus, and malignancies.…
Abstract Number: 405 • 2019 ACR/ARP Annual Meeting
Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature
Mohammad Ryadh Pokeerbux¹, Luc Dauchet ², Benjamin Lopez ³, Hélène Maillard ¹, Sandrine Morell-Dubois ¹, Eric Auxenfants ⁴ and Eric Hachulla ⁵, ¹Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, ²Department of Epidemiology, CHU Lille, University of Lille, Lille, France, ³Institute of Immunology, CHU Lille, University of Lille, Lille, France, ⁴Department of Internal Medicine, Roubaix Hospital, Roubaix, France, ⁵Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: Anti-MDA5 dermatomyositis is characterized by little or no muscle involvement, distinct cutaneous features and an increased risk of severe interstitial lung disease (ILD) with…
Abstract Number: 2843 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Victoria Werth¹, David Pearson ², Joyce Okawa ², Rui Feng ³, Josef Concha ², Basil Patel ², Emily Hejazi ², Scott Constantine ⁴, Nancy Dgetluck ⁴ and Barbara White ⁴, ¹Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ²Philadelphia Veteran Affairs Medical Center, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Lenabasum is a rationally-designed preferential cannabinoid receptor type 2 agonist that activates resolution of innate immune responses to reduce tissue inflammation and fibrotic processes.…
Abstract Number: 412 • 2019 ACR/ARP Annual Meeting
Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease
Takashi Matsushita¹, Tadahiro Kobayashi ¹, Miyu Kano ¹, Yasuhito Hamaguchi ¹ and Kazuhiko Takehara ², ¹Kanazawa University, Kanazawa, Japan, ²Department of Dermatology, Kanazawa University, Kanazawa, Japan
Background/Purpose: Patients with dermatomyositis (DM) frequently have myositis-specific autoantibodies (MSAs), which are closely associated with different clinical features. Patients with anti-aminoacyl-tRNA synthetase (ARS) antibody (Ab)…
Abstract Number: 1274 • 2019 ACR/ARP Annual Meeting
New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Sho Sasaki¹, Akira Ishii ², Mai Sugiyama ², Yuto Izumi ², Yoko Nakagome ², Kazuki Hirano ³, Takayoshi Kurabayashi ¹, Shinichi Nogi ⁴, Noriko Sasaki ², Chiho Yamada ² and Shinji Sato ⁵, ¹Tokai Universitiy School of Medicine, Isehara, Japan, ²Tokai University School of Medicine, Isehara, Japan, ³Tokai University School of Medicine, Isehara, ⁴National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan
Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS…

1
2
3
…
8
Next Page »